Trial · NCT00682565

PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina

NCT00682565, Phase 2, Completed, Cytokinetics; results first posted 2010-02-25

3 sourcestrials-2026-11-12-0.4.0

Cite this record

ConductScience Library. PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina. Trials, record NCT00682565. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00682565

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina
NCT number: NCT00682565
Status: Completed
Phases: Phase 2
Enrollment: 94 participants, actual
Lead sponsor: Cytokinetics
Conditions: Heart Failure, Myocardial Ischemia, Angina Pectoris
Interventions: CK-1827452 24mg and 6 mg iv infusion, CK-1827452 12.5mg capsule, CK-1827452 48 mg and 11 mg iv infusion, CK-1827452 25mg capsule, Placebo iv infusion, Placebo capsule
First posted: 2008-05-22
Last updated: 2018-08-21
Results first posted: 2010-02-25

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)	1 day	The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.
Secondary	Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B	1 day	The Modified Naughton Exercise Treadmill Test was employed in this study. Exercise Treadmill Test 3 (ETT-3) was performed during the last 2 hours of the 20-hour infusion of study drug or placebo. Baseline Exercise Treadmill Test (ETT-B) was performed prior to dosing.
Secondary	Increase in Exercise Duration During ETT-3 vs. ETT-B	1 day
Secondary	Participants Stopping ETT-3 for Angina at Any Stage	1 day	This Outcome Measure includes all participants who stopped ETT-3 for angina at any stage, not only those who stopped at a stage earlier than ETT-B. Note: All 9 subjects who stopped ETT-3 for angina also stopped ETT-B for angina.
Secondary	Participants With 1 mm ST Segment Depression During ETT-3	1 day	ST Segment Depression measured by Electrocardiography while performing ETT-3.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)	1 day	The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.	Participants	NUMBER
SECONDARY	Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B	1 day	The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.	Participants	NUMBER
SECONDARY	Increase in Exercise Duration During ETT-3 vs. ETT-B	1 day	The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.	seconds	MEAN
SECONDARY	Participants Stopping ETT-3 for Angina at Any Stage	1 day	The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3.	Participants	NUMBER
SECONDARY	Participants With 1 mm ST Segment Depression During ETT-3	1 day	The Safety ETT Population consists of all patients in the Randomized Population who received any study drug and who performed ETT-3. However, majority of patients did not have ECGs assessable (per protocol) for 1 mm ST depression.	Participants	NUMBER

Source ClinicalTrials.gov

Results by group15

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)	Mid Dose Active Drug	0		Participants
Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)	High Dose Active Drug	0		Participants
Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B)	All Placebo	1		Participants
Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B	Mid Dose Active Drug	4		Participants
Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B	High Dose Active Drug	2		Participants
Participants Stopping ETT-3 for Any Reason at Stage Earlier Than ETT-B	All Placebo	1		Participants
Increase in Exercise Duration During ETT-3 vs. ETT-B	Mid Dose Active Drug	41.5	Standard Deviation 113.1	seconds
Increase in Exercise Duration During ETT-3 vs. ETT-B	High Dose Active Drug	40.5	Standard Deviation 70.6	seconds
Increase in Exercise Duration During ETT-3 vs. ETT-B	All Placebo	60.1	Standard Deviation 71.2	seconds
Participants Stopping ETT-3 for Angina at Any Stage	Mid Dose Active Drug	0		Participants

1 to 10 of 15Source ClinicalTrials.gov

See all 15 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Mid Dose CK-1827452	31
Overall Study	STARTED	High Dose CK-1827452	35
Overall Study	STARTED	Placebo	29
Overall Study	COMPLETED	Mid Dose CK-1827452	30
Overall Study	COMPLETED	High Dose CK-1827452	32
Overall Study	COMPLETED	Placebo	29
Overall Study	NOT COMPLETED	Mid Dose CK-1827452	1
Overall Study	NOT COMPLETED	High Dose CK-1827452	3
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events28

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Cohort 1 Active Drug	0	31	0
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Cohort 2 Active Drug	3	34	3
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	All Placebo	1	29	1
other	Dyspnea	Respiratory, thoracic and mediastinal disorders	Total	4	94	4
other	Hypotension	Vascular disorders	Cohort 1 Active Drug	1	31	1
other	Hypotension	Vascular disorders	Cohort 2 Active Drug	1	34	1
other	Hypotension	Vascular disorders	All Placebo	0	29	0
other	Hypotension	Vascular disorders	Total	2	94	2
other	Infusion Site Pain	General disorders	Cohort 1 Active Drug	1	31	1
other	Infusion Site Pain	General disorders	Cohort 2 Active Drug	0	34	0

1 to 10 of 28Source ClinicalTrials.gov

See all 28 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Cohort 1 Active Drug
Total, all-cause mortality	Cohort 2 Active Drug
Total, all-cause mortality	All Placebo
Total, all-cause mortality	Total
Total, other adverse events	Cohort 1 Active Drug	2	31
Total, other adverse events	Cohort 2 Active Drug	7	34
Total, other adverse events	All Placebo	3	29
Total, other adverse events	Total	12	94
Total, serious adverse events	Cohort 1 Active Drug	0	31
Total, serious adverse events	Cohort 2 Active Drug	1	34

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
25453536	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release: trials-2026-11-12-0.4.0
Release manifest SHA-256: 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture: 2026-11-12
Results copy, AACT: 2026-03-23
NIH clinical studies file: 2026-11-13

Source ClinicalTrials.gov

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00682565

GET https://conductscience.org/api/trials/v1/NCT00682565/events?page=2

API reference For AI assistants